Global leader in baby care products, including nursing bottles, nipples, baby skincare and childcare items.
Global leader in baby care products, including nursing bottles, nipples, baby skincare and childcare items.
Gets new parents to try its feeding products in hospitals and maternity wards, then sells replacement bottles, nipples and skincare through baby-goods stores, drugstores and online. China is its largest overseas market, while births in Japan keep falling.
In one line: The world's Gerber/Playtex for baby bottles and nursing products.
Moat: wide (brand, IP / patents, scale). World-leading share and decades of nipple/bottle design patents trusted by hospitals globally.
Headquarters: Tokyo, Japan · Founded: 1957 · Employees: 3,042
Size Pigeon (7956.T) is a Japan Consumer Staples company (Household/Personal Care) with a market value of $1.76B, the 523rd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,344 on 18 Nov 2026.
Performance Over six months the shares gained 26.4%, against +3.4% for the median peer and -1.4% for the Japan market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 8.4% over the last twelve months (peer median +4.3%); the operating margin is 13.5% (peer median 9.9%).
Valuation It trades at 27.9× forward earnings against a peer median of 19.5× (7th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.9 points above its cost of capital (5.0% WACC).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥118B | ¥109B | ¥104B | ¥94.5B | ¥94.9B |
| Revenue growth | — | +5% | +10% | 0% | — |
| Gross profit | ¥60.3B | ¥54.8B | ¥51.4B | ¥45.5B | ¥44.8B |
| EBITDA | ¥20.6B | ¥17.8B | ¥17.0B | ¥15.8B | ¥17.1B |
| Net income | ¥10.3B | ¥8.57B | ¥8.37B | ¥7.42B | ¥8.58B |
| Free cash flow | n/a | ¥10.3B | ¥12.2B | ¥9.04B | ¥7.89B |
| Capital expenditure | n/a | ¥3.14B | ¥2.25B | ¥5.65B | ¥5.56B |
| Total debt | ¥5.66B | ¥2.15B | ¥2.70B | ¥2.72B | ¥2.77B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Pigeon 7956.T | $1.76B | +26% | +8% | 13% | 27.9× | -2.4% |
| Kimberly-Clark KMB | $65.8B | +11% | -8% | 14% | 15.2× | 5.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7956.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.4% | +1.1% | 6th highest of 21 |
| 6-month return | +26.4% | +3.4% | 5th highest of 21 |
| Distance from 52-week high | -3.7% | -24.2% | 3rd highest of 21 |
| Revenue growth (TTM) | +8.4% | +4.3% | 8th highest of 21 |
| Operating margin | 13.5% | 9.9% | 8th highest of 21 |
| Forward P/E | 27.9× | 19.5× | 7th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | -2.4% | 4.3% | 5th least demanding of 16 |
| Growth delivered (Del g) | +1.9% | +7.4% | 6th lowest of 16 |
| Hurdle (Req g minus delivered) | -4.3 pp | -2.6 pp | 8th least demanding of 16 |
| ROIC minus cost of capital | +13.9 pp | +5.1 pp | 4th highest of 20 |
| EV / EBITDA | 12.3× | 10.3× | 6th most expensive of 14 |
| Net debt / EBITDA | -1.5× | -0.6× | 7th least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pigeon 7956.T | Japan | $1.76B | +26% | +8% | 13% | 27.9× | -2.4% | +1.9% |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.69B | -33% | +7% | 9% | 19.1× | 2.6% | +15.3% |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.62B | +9% | -6% | 2% | 45.5× | n/a | n/a |
| Shanghai Jahwa United 600315.SS | China | $1.61B | -15% | +9% | 2% | 15.4× | 15.3% | -2.1% |
| AMOREPACIFIC 002790.KS | South Korea | $1.61B | +2% | +9% | 9% | 8.5× | -5.7% | -1.3% |
| Energizer ENR | United States | $1.94B | +71% | 0% | 17% | 9.1× | -5.1% | -0.5% |
| Emami EMAMILTD.NS | India | $1.94B | -5% | +13% | 20% | 23.4× | 21.5% | +5.6% |
| Pola Orbis 4927.T | Japan | $2.04B | +15% | +1% | 11% | 30.6× | -2.0% | -0.7% |
| Kolmar Korea 161890.KS | South Korea | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% | +15.5% |
| Harbin Fuerjia Technology 301371.SZ | China | $1.51B | -39% | +28% | 20% | 21.4× | 7.5% | +3.6% |
| Blue Moon 6993.HK | Hong Kong | $2.07B | -4% | -2% | -2% | 103.3× | n/a | n/a |
| KOSE 4922.T | Japan | $2.16B | +16% | +4% | 5% | 29.9× | n/a | n/a |
| Intercos ICOS.MI | Italy | $1.43B | +12% | -5% | 9% | 18.9× | 4.3% | +11.5% |
| Softcare 2698.HK | Hong Kong | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% | +20.9% |
| Chongqing Baiya Sanitary Products 003006.SZ | China | $1.35B | +27% | 0% | 3% | 37.3× | 28.8% | +22.8% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.37B | -30% | -2% | 24% | 27.0× | 21.2% | +7.4% |
| Edgewell Personal Care EPC | United States | $1.30B | +67% | -10% | 7% | 14.2× | n/a | n/a |
| Giant Biogene 2367.HK | Hong Kong | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% | +34.9% |
| Cosmax 192820.KS | South Korea | $2.51B | +53% | +25% | 8% | 18.8× | n/a | n/a |
| Winner Medical 300888.SZ | China | $2.53B | -6% | +4% | 11% | 19.9× | -5.2% | -2.6% |
| Gillette India GILLETTE.NS | India | $2.53B | -5% | +8% | 28% | 37.1× | 14.9% | +13.0% |